Preoperative chemotherapy response and survival in patients with colorectal cancer peritoneal metastases.
chemotherapy response
colorectal cancer peritoneal metastases
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
16 Jul 2024
16 Jul 2024
Historique:
revised:
26
06
2024
received:
13
05
2024
accepted:
01
07
2024
medline:
16
7
2024
pubmed:
16
7
2024
entrez:
16
7
2024
Statut:
aheadofprint
Résumé
Treatment guidelines provided by PRODIGE-7 recommend perioperative systemic chemotherapy before cytoreductive surgery (CRS) for colorectal cancer peritoneal metastases (CRPM). Toxicity with multimodal treatment needs to be better defined. Chemotherapy response and impact on survival have not been reported. We assessed CRPM patients who received systemic oxaliplatin/irinotecan before CRS (preoperative) with Mitomycin C (35 mg/m
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Journal of Surgical Oncology published by Wiley Periodicals LLC.
Références
Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open‐label, phase 3 trial. Lancet Oncol. 2021;22(2):256‐266. http://www.ncbi.nlm.nih.gov/pubmed/33476595
Sánchez‐Hidalgo JM, Rodríguez‐Ortiz L, Arjona‐Sánchez Á, et al. Colorectal peritoneal metastases: optimal management review. World J Gastroenterol. 2019;25(27):3484‐3502. http://www.ncbi.nlm.nih.gov/pubmed/31367152
Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386‐1422. https://linkinghub.elsevier.com/retrieve/pii/S0923753419347544
Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol. 2016;Dec 17(12):1709‐1719. Available from https://linkinghub.elsevier.com/retrieve/pii/S1470204516305009
Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (Cairo): A phase III randomised controlled trial. The Lancet. 2007;370(9582):135‐142. Available from https://linkinghub.elsevier.com/retrieve/pii/S0140673607610861
Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non‐gynecologic malignancies. Cancer. 2000;88(2):358‐363. doi:10.1002/(SICI)1097‐0142(20000115)88:2%3C358::AID‐CNCR16%3E3.0.CO;2‐O
Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30(3):263‐267. doi:10.1200/JCO.2011.37.1039
Morris VK, Kennedy EB, Baxter NN, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol. 2023;41(3):678‐700. doi:10.1200/JCO.22.01690
Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow‐up. Ann Oncol. 2023;34(1):10‐32. doi:10.1016/j.annonc.2022.10.003
Goéré D, Glehen O, Quenet F, et al. Second‐look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP‐PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020;21(9):1147‐1154. http://www.ncbi.nlm.nih.gov/pubmed/32717180
Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open‐label, randomised trial. The Lancet Gastroenterology & Hepatology. 2019;4(10):761‐770. https://linkinghub.elsevier.com/retrieve/pii/S2468125319302390
Arjona‐Sánchez A, Espinosa‐Redondo E, Gutiérrez‐Calvo A, et al. Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer. JAMA Surgery. 2023;158(7):683‐691.
Bakkers C, Rovers KP, Rijken A, et al. Perioperative systemic therapy versus cytoreductive surgery and HIPEC alone for resectable colorectal peritoneal metastases: Patient‐Reported outcomes of a randomized phase II trial. Ann Surg Oncol. 2023;30(5):2678‐2688. doi:10.1245/s10434‐023‐13116‐z
Passot G, You B, Boschetti G, et al. Pathological response to neoadjuvant chemotherapy: A new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014;21(8):2608‐2614. doi:10.1245/s10434‐014‐3647‐0
Sugarbaker PH, Chang D. Revised prognostic indicators for treatment of lymph node positive colorectal peritoneal metastases. J Surg Oncol. 2022;125(5):889‐900. doi:10.1002/jso.26792
Ghabra S, Desale S, Sugarbaker PH. Clinical and histopathologic features of 35 patients treated for colorectal peritoneal metastases who survived 5 years. Dis Colon Rectum. 2023;66(10):1329‐1338. doi:10.1097/DCR.0000000000002448
Sousa IVF, Lopes JMD, Nogueiro JPM, Costa TR, Barbosa LER, Aral MMM. Histological tumor response predicts clinical outcome in patients with colorectal peritoneal metastasis treated with preoperative chemotherapy followed by cytoreduction and HIPEC. Pleura Peritoneum. 2023;8(1):37‐44. doi:10.1515/pp‐2022‐0117/html
Thies S, Langer R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol. 2013;3:262. http://www.ncbi.nlm.nih.gov/pubmed/24109590
U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE).v.5.0. Cancer Ther Eval Progr [Internet]. 2017:155.
Larsen SG, Goscinski MA, Dueland S, et al. Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. Br J Cancer. 2022;126(5):726‐735.
Bokemeyer C, Cutsem EV, Rougier P, et al. Addition of cetuximab to chemotherapy as first‐line treatment for KRAS wild‐type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012;48(10):1466‐1475.
Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol. 1998;9(10):1053‐1071. https://linkinghub.elsevier.com/retrieve/pii/S0923753419482045
Ubink I, Bolhaqueiro ACF, Elias SG, et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. Br J Surg. 2019;106(10):1404‐1414.
Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nature Med. 2015;21(11):1350‐1356. http://www.nature.com/articles/nm.3967
Barriuso J, Nagaraju RT, Belgamwar S, et al. Early adaptation of colorectal cancer cells to the peritoneal cavity is associated with activation of “stemness” programs and local inflammation. Clin Cancer Res. 2021;27(4):1119‐1130. doi:10.1158/1078‐0432.CCR‐20‐3320
Tinsley N, Nagaraju R, O'Dwyer S, et al. Cytoreductive surgery and HIPEC in colorectal cancer peritoneal metastases (CRPM): real‐world outcomes in systemic anticancer treatment–naïve patients. J Clin Oncol. 2023;41(4_suppl):39. doi:10.1200/JCO.2023.41.4_suppl.39
Kranenburg O, Speeten K, Hingh I. Peritoneal metastases from colorectal cancer: defining and addressing the challenges. Front Oncol. 2021;11(March):1‐11.
ten Hoorn S, de Back TR, Sommeijer DW, Vermeulen L. Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and Meta‐Analysis. J Natl Cancer Inst. 2022;114(4):503‐516. doi:10.1093/jnci/djab106